Madrigal Pharmaceuticals Inc. (MDGL)

Business: Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases.

IPO Date: 06-Feb-2007

Chairman & CEO: Dr. Paul A. Friedman M.D.

Founder, Chief Medical Officer, Pres of R&D and Director: Dr. Rebecca A. Taub M.D.

Listing: NASDAQ: MDGL

Country: United States

Headquarters: West Conshohocken, PA

Website: https://www.madrigalpharma.com

Market cap: $1,258.64 Mln

Revenue (TTM): $0.02 Mln

Earnings (TTM): $-246.82 Mln

Cash: $219.95 Mln

Total Debt: $0.70 Mln

Insider's Holding: 18.77%

Liquidity: Low

52 Week range: $52.33 - 105.93

Shares outstanding: 17,103,400

10 Years Aggregate:

• CFO: $-730.45 Mln
• EBITDA: $-938.41 Mln
• Net Profit: $-926.20 Mln